Home » Stocks » RNLX

Renalytix AI PLC (RNLX)

Stock Price: $13.35 USD -0.69 (-4.91%)
Updated November 30, 2:03 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 480.80M
Revenue (ttm) n/a
Net Income (ttm) -14.59M
Shares Out 36.01M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $13.35
Previous Close $14.04
Change ($) -0.69
Change (%) -4.91%
Day's Open 14.04
Day's Range 12.62 - 14.03
Day's Volume 81,403
52-Week Range 10.18 - 17.30

More Stats

Market Cap 480.80M
Enterprise Value 398.80M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 36.01M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.41
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 109,488
Short Ratio 6.04
Short % of Float n/a
Beta 1.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.67
Revenue n/a
Operating Income n/a
Net Income -14.59M
Free Cash Flow n/a
Net Cash 82.00M
Net Cash / Share 2.28
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -13.95%
ROE -26.70%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(40.15% upside)
Current: $13.35
Target: 18.71
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-10.32-42.34
Net Income9.84-42.30
Shares Outstanding59.0842.56
Earnings Per Share-0.34-1.98
Operating Cash Flow-9.52-6.16
Capital Expenditures-1.23-0.31
Free Cash Flow-10.75-6.47
Cash & Equivalents14.289.20
Total Debt0.26-
Net Cash / Debt14.029.20
Book Value15.918.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Renalytix AI PLC
Country United Kingdom
Employees 8
CEO James McCullough

Stock Information

Ticker Symbol RNLX
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: RNLX
IPO Date July 17, 2020


Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.